Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioRestorative Therapies, Inc. (NASDAQ: BRTX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. BioRestorative is a biotechnology issuer that develops adult stem cell-based therapies and products, and its filings offer detailed insight into the disc/spine, metabolic, and BioCosmeceutical programs that it highlights in its public communications.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which BioRestorative identifies in its S-1 registration statement as being incorporated by reference. These reports discuss risk factors, management’s discussion and analysis, and financial statements related to its clinical-stage BRTX-100 program for degenerative disc disease, the ThermoStem® metabolic platform targeting obesity and metabolic disorders, and its commercial BioCosmeceutical activities.
Investors can also examine current reports on Form 8-K that BioRestorative files to describe material events. Recent examples include disclosures about a registered direct offering of common stock with concurrent private placement of unregistered warrants, the use of proceeds for BRTX-100 clinical trials and ThermoStem® preclinical research, stockholder meeting results, and the release of quarterly financial results and corporate presentations.
In addition, this page surfaces registration statements such as Form S-1 and Form S-3, where BioRestorative outlines the terms of offerings, the status of its common stock on the NASDAQ Capital Market, and the documents incorporated by reference. Users interested in executive compensation, governance, and voting matters can consult the company’s definitive proxy statement on Schedule 14A.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as capital raises, clinical program disclosures, and stock incentive plan changes. Real-time updates from EDGAR ensure that new BRTX filings, including Forms 3, 4, and 5 related to insider transactions when available, are added promptly for ongoing analysis.
BioRestorative Therapies, Inc. reported that its Compensation Committee approved cash bonuses for executive officers for the year ended December 31, 2025, and presented an updated Summary Compensation Table.
For 2025, CEO Lance Alstodt received salary of $596,666, a discretionary cash bonus of $300,000 and total compensation of $2,409,167. VP of Research and Development Francisco Silva received salary of $566,666, a $287,500 discretionary bonus and total compensation of $2,322,916. CFO Robert Kristal received salary of $343,750, a $140,000 discretionary bonus and total compensation of $801,750. The bonuses relate to 2025 services and are to be paid in 2026.
Registration covers up to 15,285,715 shares of common stock underlying outstanding warrants. This prospectus registers 14,285,715 shares issuable upon exercise of Common Stock Warrants (exercise price $0.35) and 1,000,000 shares issuable upon exercise of Placement Agent Warrants (exercise price $0.4375), each exercisable until February 13, 2031. The filing states 25,478,170 shares outstanding as of April 28, 2026 and a post‑exercise share count of up to 40,763,885 assuming full exercise. The company estimates gross proceeds of $5,437,500 if all warrants are exercised for cash and discloses a cashless exercise feature if registration is not effective.
BioRestorative Therapies, Inc. filed Amendment No. 1 to its Post-Effective Amendment No. 1 to the Form S-1 registration statement (Registration No. 333-293322) on April 27, 2026. This amendment is exhibit-only and files a revised opinion of counsel as Exhibit 5; the prospectus and remaining Part II are unchanged.
The filing lists the registrant's principal office in Melville, New York, identifies Nevada as the state of incorporation, and references multiple exhibits and agreements incorporated by reference, including an At the Market Offering Agreement dated November 6, 2024.
BioRestorative Therapies, Inc. furnished an updated corporate presentation that may be used at conferences and investor meetings. The deck is available on the company’s website and is attached as Exhibit 99.1.
The presentation is furnished under a disclosure item and is not deemed filed or subject to Section 18 liability, nor automatically incorporated into other Securities Act or Exchange Act filings.
BioRestorative Therapies, Inc. files a Post-Effective Amendment to its Form S-1 to register up to 15,285,715 shares of common stock issuable upon exercise of outstanding warrants issued in February 2026.
The amendment incorporates the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates offering details for the 14,285,715 Common Stock Warrants (exercise price $0.35) and 1,000,000 Placement Agent Warrants (exercise price $0.4375), exercisable through February 13, 2031. The prospectus notes going-concern disclosure and states estimated gross proceeds of $5,437,500 if all warrants are exercised for cash.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment increasing authorized common shares from 75,000,000 to 1,500,000,000 and to allow adjournment of the special meeting if more proxies are needed. As of April 6, 2026, 25,478,170 common shares were outstanding.
The company cites future capital raising for clinical trials of BRTX-100, its ThermoStem program, biocosmeceuticals development, employee plans, and securities conversions as key uses for additional shares. It warns that future issuances could dilute existing holders’ ownership and notes it currently lacks preemptive rights for stockholders.
The proxy also discloses that the company received a Nasdaq notice on March 26, 2026 for not meeting the $1.00 minimum bid requirement and has until September 22, 2026 to regain compliance. The board highlights existing anti-takeover provisions but states it has no current plans to use additional shares or preferred stock to entrench management.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment to increase authorized common shares from 75,000,000 to 1,500,000,000 at a Special Meeting on May 26, 2026. The Board also seeks authority to adjourn the meeting to solicit additional proxies if needed. The record date for voting is April 6, 2026. The proxy materials and the 2025 Form 10-K will be made available to stockholders by April 13, 2026. The Board states it has no definitive plans to issue the newly authorized shares but says additional shares would permit future capital raises and other corporate uses. The company disclosed a Nasdaq notice of noncompliance with the $1.00 minimum bid price and has until September 22, 2026 (an initial 180-day cure period from a March 26, 2026 notice) to regain compliance.
BioRestorative Therapies, Inc. files its annual report describing progress across its cell therapy pipeline and capital raising activities. The company is developing BRTX-100 for chronic lumbar disc disease, a ThermoStem metabolic program, and a commercial biocosmeceuticals line.
BRTX-100 received FDA Fast Track designation, completed enrollment of a 99-patient Phase 2 trial, and showed encouraging blinded data with over 74% of subjects achieving major functional improvement and over 72% reporting substantial pain reduction at 52 weeks without serious safety issues. The FDA also granted a Type B meeting, after which Phase 3 enabling work began.
ThermoStem gained additional patents in Europe, Israel, Japan and is advancing preclinical work using brown fat–derived stem cells. The company raised capital through warrant exercises and multiple equity offerings totaling more than $16 million in gross proceeds, but still reports no significant revenue and expects current funds may not cover planned trials and operations for the year ahead.
BioRestorative Therapies, Inc. filed an amendment to a Schedule 13G/A stating that Todd Hale Morrison beneficially owned 0 shares of the company’s common stock as of the close of business on 02/23/2026.
The filing lists 0.0% ownership and zero voting or dispositive power across all categories, and is signed by the reporting person.